Financial Data and Key Metrics Changes - ClearPoint Neuro reported total revenues of $37 million for the year ended December 31, 2025, compared to $31.4 million in 2024, marking an increase of approximately 18% [10] - The gross margin for the full year 2025 was 61%, consistent with 2024 [12] - Net cash flows used in operating activities for 2025 were $23.9 million, an increase of $15 million from 2024, primarily due to a higher net loss and pay down of accounts payable [19] Business Line Data and Key Metrics Changes - Biologics and Drug Delivery revenue increased by 10% to $19 million in 2025, up from $17.3 million in 2024, driven by increased product sales [11] - Neurosurgery navigation revenue grew to $14.8 million in 2025, including $1.2 million from the IRRAS product line, attributed to an increased installed base and the full market release of new systems [11] - Capital equipment and software revenue was $3.1 million for 2025, showing a slight decrease compared to the previous year [12] Market Data and Key Metrics Changes - The company expects revenues for 2026 to be in the range of $52 million to $56 million, reflecting factors such as FDA communications regarding rare diseases and integration efforts from the IRRAS acquisition [8] - ClearPoint is participating in more than 25 active clinical trials and has over 60 active biopharma partners, with more than 10 partner programs accepted for FDA expedited review [5][24] Company Strategy and Development Direction - ClearPoint Neuro is focused on developing a complete neuro ecosystem for minimally invasive treatments, including cell and gene therapies [4] - The company has entered two phases of growth strategy: "Fast Forward" to penetrate a $1 billion market and "Essential Everywhere" to build a new market for commercial cell and gene therapy delivery [6][7] - The company aims to achieve 20% market share in various segments, including pre-commercial biologics and drug delivery, neurosurgery navigation, laser therapy, and neurocritical management [34] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's strong position and momentum going into 2026, highlighting the successful integration of the IRRAS acquisition and the potential for significant revenue growth [21] - The management noted that the FDA's recent communications regarding rare diseases have influenced revenue guidance, leading to a more cautious approach in forecasting [41] Other Important Information - The company has invested over $100 million in the past five years to build a strong foundation, including a robust pipeline of development programs and an expanded manufacturing footprint [5] - ClearPoint's unique biologics and drug delivery ecosystem is expected to play a crucial role in the future of neurological treatments, with a focus on supporting biopharma partners [4][26] Q&A Session Summary Question: Clarification on 2026 guidance and organic growth - Management explained that the guidance was tightened due to FDA communications on rare diseases and the integration of IRRAS, with expectations for balanced organic and inorganic growth [38][46] Question: Pathway to $200 million revenue - Management indicated that they expect to grow at a rate of 15%-20% as they capture market share across their segments, with potential for significant revenue bumps from large GLP studies [48][50] Question: Updates on expedited review partners - Management confirmed that there are over 10 partners in expedited review pathways, with indications including Parkinson's disease and drug-resistant epilepsy, providing higher confidence in potential revenue [60][61] Question: Timeline for expansion in neuro-oncology - Management discussed the strength of their commercial team and the importance of upcoming clinical data to support expansion into neuro-oncology, indicating a serious commitment to this market [62]